A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 291 participants.
Also called NCT04591626
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 291 participants
- Sponsor
- Registry
-
NCT04591626
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT04591626. Randomized; double masking; primary purpose treatment. Start 2020-12-07 (actual); primary completion 2022-04-28 (actual). Results posted on 2023-05-24.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes
- Acronym
- AWARD-CHN3
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Dulaglutide
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Insulin Glargine
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct04591626- Content hash
95423a741bedd86af0dae43f25482597832705eb033357cfe0765eef9303cde6